Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MTI-31 (LXI-15029) is a potent, orally active and highly selective inhibitor of mTORC1 and mTORC2. MTI-31 is selective for mTOR (Kd: 0.20 nM) versus PIK3CA, PIK3CB and PIK3G with <5,000 fold selectivity in mTOR binding assays. MTI-31 shows an IC50 of 39 nM for mTOR in LANCE assay of mTOR substrate phosphorylation with 100 μM ATP[1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 293.00 | |
5 mg | In stock | $ 622.00 | |
10 mg | In stock | $ 976.00 | |
25 mg | In stock | $ 1,450.00 | |
50 mg | In stock | $ 1,960.00 | |
100 mg | In stock | $ 2,630.00 |
Description | MTI-31 (LXI-15029) is a potent, orally active and highly selective inhibitor of mTORC1 and mTORC2. MTI-31 is selective for mTOR (Kd: 0.20 nM) versus PIK3CA, PIK3CB and PIK3G with >5,000 fold selectivity in mTOR binding assays. MTI-31 shows an IC50 of 39 nM for mTOR in LANCE assay of mTOR substrate phosphorylation with 100 μM ATP[1]. |
Targets&IC50 | mTOR:0.2 nM(Kd) |
In vitro | MTI-31 (0.01-100 μM) elicits a potent and more substantial inhibition of cell growth than that of Rapamycin[1]. Treatment with MTI-31 for 6 h demonstrates a dose-dependent inhibition of both the mTORC1 substrates P-S6K1(T389), P-S6(S235/6), P-4EBP1(T70) and mTORC2 substrate P-AKT(S473), achieving 50% inhibition at ≤0.12 μM in three representative tumor cell lines harboring mTOR pathway dysregulation (786-O renal, U87MG glioma and MDA-MB-453 breast)[1]. MTI-31-induced apoptosis requires mTORC2-regulated Bim- and GSK3 activity[1]. |
In vivo | MTI-31(5-40 mg/kg; orally) is efficacious in several tumor models harboring HER2+/PIK3CAmut and/or PTEN-deficiency exemplified by MDA-MB-453 and 786-O[1]. Treatment of tumor bearing nude mice with orally administered MTI-31 inhibits growth of H1975 tumors (25 mg/kg/d; orally) or U87MG tumors (30 mg/kg/d; orally)[2]. |
Synonyms | MTI-31, LXI-15029 |
Molecular Weight | 474.55 |
Formula | C26H30N6O3 |
CAS No. | 1567915-38-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 8.33 mg/mL (17.55 mM), Sonication and heating to 60℃ are recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
MTI-31 1567915-38-1 PI3K/Akt/mTOR signaling mTOR mTOR kinase inhibitor tissue factor LXI 15029 mTORC2 mTOR inhibitor Inhibitor EGFR mutant cancer mTOR-TF axis Mammalian target of Rapamycin MTI31 apoptosis inhibit MTI 31 mTORC1 lipid metabolism LXI-15029 LXI15029 tumor microenvironment inhibitor